Business Wire

Entrust Datacard Makes Strategic Investment in UK-Based CensorNet and Acquires its Multi-Factor Authentication Technology Solution

Del

Entrust Datacard, a leading provider of trusted identity and secure transaction technology solutions, today announced that it has made a strategic investment in CensorNet, the complete cloud security company, to propel Entrust Datacard toward achieving real-time threat awareness with enhanced pattern analysis for continuous authentication capabilities. Entrust Datacard has also acquired Copenhagen-based SMS Passcode, CensorNet’s adaptive multi-factor authentication technology solution. The strategic acquisition of the SMS Passcode technology and the investment in CensorNet’s USS platform further establishes Entrust Datacard as an innovative authentication solution provider and allows the company to further expand its global footprint throughout DACH/Benelux and The Nordics.

CensorNet’s USS platform, which includes a cloud access security broker (CASB), multi-factor authentication, and web and email security, will bolster new offerings for Entrust Datacard across authentication, PKI and SSL. Additionally, the collaboration will enhance the Entrust Datacard intelligent Authentication Insight Engine by accelerating its behavior and pattern capabilities for more real-time, intelligent decision-making, improving security and the user experience for the next generation of threats and compliance needs.

“Identity-centric data analysis is in CensorNet’s DNA, and identity assurance capabilities in ours,” said Todd Wilkinson, president and CEO for Entrust Datacard. “This new relationship and investment in CensorNet presents opportunities for collaboration to enhance both companies’ offerings and re-shape the market together.”

For greater collaboration between the companies, Entrust Datacard CEO Todd Wilkinson will join CensorNet’s board of directors and the SMS Passcode team will integrate with the larger Entrust Datacard authentication team.

In a quickly-changing IT and threat landscape, the need for a more seamless, frictionless and secure customer experience has never been greater. The acquisition of SMS Passcode will allow Entrust Datacard to better serve customers by integrating the solution’s technology with its IntelliTrust SaaS authentication solution, expanding USS capabilities to Entrust Datacard customers while adding advanced mobile and cloud capabilities to SMS Passcode customers.

“CensorNet and Entrust Datacard have a shared vision for real-time identity centric security that can be achieved faster and with greater impact together rather than separately,” said Ed Macnair, CEO for CensorNet. “The acquisition of SMS Passcode will benefit the broader IAM market as well as SMS Passcode customers, and this new relationship will continue serving customers as Entrust Datacard builds upon existing partnerships and enhances our USS offering.”

Entrust Datacard has a long history of innovating and expanding both geographically and technologically to provide solutions that reflect changing market conditions. Continuing this approach, the SMS Passcode acquisition and investment in CensorNet’s USS platform represents a significant step toward both a holistic security approach and global presence for the organization. At a time when other security players are going through large, complex mergers or acquiring and shelving smaller innovators, Entrust Datacard is building strong partnerships through targeted investments and acquisitions.

“SMS Passcode is an established multi-factor authentication (MFA) leader in DACH/Benelux and The Nordics, making it a natural fit for our acquisition strategy,” said Wilkinson. “The MFA technology, as well as the USS platform, will be strong complements to the Entrust Datacard portfolio of solutions.”

The acquisition was signed and finalized on June 30, 2018. Terms of the acquisition are undisclosed.

For more information about Entrust Datacard’s authentication solutions, visit: https://www.entrustdatacard.com/products/categories/authentication.

About Entrust Datacard Corporation

Consumers, citizens and employees increasingly expect anywhere-anytime experiences — whether they are making purchases, crossing borders, accessing e-gov services or logging onto corporate networks. Entrust Datacard offers the trusted identity and secure transaction technologies that make those experiences reliable and secure. Solutions range from the physical world of financial cards, passports and ID cards to the digital realm of authentication, certificates and secure communications. With more than 2,200 Entrust Datacard colleagues around the world, and a network of strong global partners, the company serves customers in 150 countries worldwide. For more information, visit www.entrustdatacard.com.

About CensorNet

CensorNet, the complete cloud security company, helps organizations to effectively manage and control the use of cloud applications in their business. The company provides a unified and multi-layered approach to securing the cloud via its purpose built, multi-functional cloud security platform that delivers integrated web security, email security, CASB and adaptive multi-factor authentication. This provides organizations with security-focused visibility and control over user access, data and assets to allow access while controlling outcomes and allows organizations to address the security, audit, compliance and productivity issues associated with the use of cloud applications and devices. CensorNet enables organizations to control Shadow IT, safely implement BYOD initiatives and protect from cyber threats. With more than 4000 customers and over 1.3 million users worldwide, the company is headquartered in Basingstoke, UK and has further offices in Austin, US; Copenhagen, Denmark and Munich, Germany. For more information, visit www.censornet.com

Contact information

Entrust Datacard Contact:
Heather Morris, +1 952.988.1745
Director, Global Communications
heather.morris@entrustdatacard.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma21.10.2018 10:45Pressemelding

Incyte Corporation (Nasdaq:INCY) announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment. In patients with FGFR2 translocations who were followed for at least eight months, interim study results demonstrated an overall response rate (ORR) of 40 percent, the primary endpoint, and a median progression free survival (PFS) of 9.2 months, a key secondary endpoint. These results are being presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany in a poster presentation on Sunday, October 21 from 12:45 p.m. CEST to 1:45 p.m. CEST (6:45 a.m. ET to 7:45 a.m. ET). (Location: Hall A3 – Poster Area Networking Hub; Abstract #756P) “We are pleased to share updated interim results from our ongoing FIGHT-202 trial

Servier and Taiho Oncology Announce Phase III LONSURF® Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer21.10.2018 09:10Pressemelding

Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or are intolerant to previous lines of therapy. The study met its primary endpoint of prolonged overall survival (OS) and secondary endpoint measures of progression-free survival (PFS) consistently supported the OS results, as well as continuing to demonstrate the predictable safety and tolerability profile of trifluridine/tipiracil. Data from TAGS was presented by Dr. Hendrik-Tobias Arkenau, Executive Medical Director of the Sarah Cannon Research Institute UK and an investigator for TAGS, at the ESMO 2018 Congress in Munich, Germany during an oral session (Abstract #LBA25). The study results were simultaneously published in

Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting20.10.2018 22:30Pressemelding

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent

Manchester United and True Religion Launch Denim Range19.10.2018 17:37Pressemelding

Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion

Arch Insurance Announces Strategic Leadership Changes19.10.2018 13:10Pressemelding

Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These

Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 12:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an